Updated efficacy including genetic subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously-treated CLL/SLL
John Pagel, Jennifer Brown, Peter Hillmen, Susan O'Brien et autres
Updated efficacy including genetic subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously-treated CLL/SLL
us, au, at, fr, ie, it, es, Afrique du Sud (code pays fourni par la source)